EUVIMEDSkopri EUVIMED
Systematische ÜbersichtMetaanalyseOpen access

Patient-Facing AI-Enabled Digital Health Technologies and Quality of Life in Cancer: Systematic Review and Exploratory Meta-Analysis

Anica Ilic iD, Lene Kristine Juvet iD, Patrick Cairns iD, Kristen Elizabeth Thompson Thornton iD, Hanne Cathrine Lie iD

JMIR mHealth and uHealth · 2026

DOI: 10.2196/94793 ↗

At a glance

Systematische Übersicht in JMIR mHealth and uHealth, 2026. Written by Anica Ilic and 4 co-authors. Institution: Department of Behavioural Medicine, Institute of Basic Medical Sciences, Faculty of Medicine, University of Oslo, Postboks 1111 Blindern, Oslo, 0317,…. Major MEDLINE topics: Quality of Life, Neoplasms, Artificial Intelligence. 48 references. The full text is freely available in PubMed Central. Funded by: Swiss National Science Foundation.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Background

Cancer affects multiple physical, psychological, and social aspects of an individual’s life. Cancer survivors frequently report unmet needs long after diagnosis and require ongoing support. AI is increasingly embedded in patient-facing digital health technologies (DHTs) in oncology, yet its impact on different domains of patients’ and survivors’ health-related quality of life (HRQOL) remains unclear.

Objective

This systematic review aims to (1) examine how AI has been integrated into patient-facing DHTs designed to support cancer survivors, (2) narratively synthesize the potential effects of these technologies on HRQOL and provide preliminary quantitative estimates through an exploratory meta-analysis, and (3) explore broader changes in additional patient-reported outcomes (PROs; secondary aim).

Methods

PubMed, PsycINFO, Embase, Scopus, CINAHL, and the Cochrane Library were searched for articles published between January 2020 and August 2025. Reference lists of included articles were hand-searched for additional eligible studies. Eligible studies enrolled cancer survivors of any age and disease stage, evaluated a patient-facing DHT with AI components, and assessed HRQOL. Nonoriginal research and non-English reports were excluded. Risk of bias was assessed in all controlled studies using RoB 2 (revised Cochrane risk of bias 2) or ROBINS-I V2 (Risk of Bias in Non-Randomized Studies—of Interventions, Version 2), according to study design. Data on HRQOL and other PROs were synthesized narratively, and exploratory random-effects meta-analyses were conducted for HRQOL domains.

Results

Eight reports from 7 studies from China and the United States (N=2867 participants) met the inclusion criteria, and 3 (n=292 participants) contributed to the exploratory meta-analysis. All studies included adults with various cancers at different stages and times since diagnosis. Most studies showed low risk of bias or some concerns (RoB 2), but one was evaluated as having a serious risk of bias (ROBINS-I V2). AI applications ranged from symptom monitoring to targeted education. The narrative synthesis suggested positive effects on selected HRQOL domains, particularly general health, with more pronounced effects in studies conducted in China. Exploratory meta-analyses demonstrated provisional moderate positive effects on global health (Hedges g=0.77, 95% CI 0.15‐1.40) and social functioning (Hedges g=0.75, 95% CI 0.08‐1.42), but no effects on physical functioning, role functioning, or emotional well-being. Other PROs indicated generally high user satisfaction and adherence, improved mental health outcomes, and reductions in physical symptoms. Only minor and mild adverse events were reported.

Conclusions

Current evidence, although limited, suggests that AI-enabled patient-facing DHTs may benefit survivors’ HRQOL and other PROs, particularly in early survivorship. However, our findings are based on small and heterogeneous studies and should therefore be interpreted with caution. Robust trials with adequate sample sizes, longer follow-up, and appropriate control conditions, including DHTs without AI components, are needed to determine the specific contribution of AI. Trial Registration PROSPERO CRD420251021466; https://www.crd.york.ac.uk/PROSPERO/view/CRD420251021466

Subjects

MeSH terms (MEDLINE)

Quality of LifeNeoplasmsArtificial IntelligenceHumansDigital HealthPatient Reported Outcome Measures

Author keywords

AIdigital healthneoplasmspatient-reported outcome measuresquality of life

Authors and institutions

  • Department of Behavioural Medicine, Institute of Basic Medical Sciences, Faculty of Medicine, University of Oslo, Postboks 1111 Blindern, Oslo, 0317, Norway.
  • Division of Infection Control, Norwegian Institute of Public Health, Oslo, Norway.
  • Department of Nursing and Health Sciences, Faculty of Health and Social Sciences, University of South-Eastern Norway, Borre, Norway.

ORCID profiles: Anica Ilic, Lene Kristine Juvet, Patrick Cairns, Kristen Elizabeth Thompson Thornton, Hanne Cathrine Lie

Funding

  • Swiss National Science Foundation

Cite

APA

Ilic, A., Juvet, L. K., Cairns, P., Thornton, K. E. T., & Lie, H. C. (2026). Patient-Facing AI-Enabled Digital Health Technologies and Quality of Life in Cancer: Systematic Review and Exploratory Meta-Analysis. JMIR mHealth and uHealth. https://doi.org/10.2196/94793

Vancouver

Ilic A, Juvet LK, Cairns P, Thornton KET, Lie HC. Patient-Facing AI-Enabled Digital Health Technologies and Quality of Life in Cancer: Systematic Review and Exploratory Meta-Analysis. JMIR mHealth and uHealth. 2026. doi:10.2196/94793

BibTeX
@article{Ilic2026,
  author = {Ilic, Anica and Juvet, Lene Kristine and Cairns, Patrick and Thornton, Kristen Elizabeth Thompson and Lie, Hanne Cathrine},
  title = {Patient-Facing AI-Enabled Digital Health Technologies and Quality of Life in Cancer: Systematic Review and Exploratory Meta-Analysis},
  journal = {JMIR mHealth and uHealth},
  year = {2026},
  doi = {10.2196/94793}
}
Start for free →